Skip to content

Efficacy and safety of Flurbiprofen Gel Patch in the treatment of acute ankle injury: A single-center randomized controlled clinical trial

Efficacy and safety of Flurbiprofen Gel Patch in the treatment of acute ankle injury: A single-center randomized controlled clinical trial

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058325
Enrollment
Unknown
Registered
2022-04-06
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ankle sprain

Interventions

Experimental group:Use flurbiprofen patch
Control Group:Use the ointment of Ritalin

Sponsors

Shenzhen Second People’s Hospita
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1) age =18 years and < 60 years; 2) a clear history of acute ankle sprain in 3 days, resulting in swelling and pain of ankle and Dyskinesia, no open injury; 3) x-ray examination excluded ankle fracture or dislocation and instability; 4) the degree of ankle injury was confirmed by symptom examination as grade I and Grade II (not including Grade III)

Exclusion criteria

Exclusion criteria: 1) age < 18 or =60 years; 2) Abnormal Liver and kidney function; 3) Atypical parkinsonism caused by drugs, metabolic diseases, encephalitis, or degenerative diseases (such as progressive supranuclear numbness and Multiple System Atrophy) ; 4) allergic to drugs and food; 5) active neoplastic disease; 6) history of mental illness and use of antipsychotic before months; 7) pregnant breast-feeding; 8) Ankle Sprain Degree III confirmed by physical examination.

Design outcomes

Primary

MeasureTime frame
Circumference measurement of ankle joint;Vas Score;Ankle function;

Countries

China

Contacts

Public ContactLi Wencui
13923750767@163.com13923750767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026